Small molecule · developed by NeuroSense Therapeutics
PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib. It is studied in pharmacokinetics.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05232461 | Phase 1 | Pharmacokinetics | Completed | NRSN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pharmacokinetics
Updated Oct 25, 2026. Something wrong or missing? Report it on the NRSN page.
See NRSN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NRSN catalysts and pipeline →